Other stimulant dependence with withdrawal
ICD-10 F15.23 is a billable code used to indicate a diagnosis of other stimulant dependence with withdrawal.
F15.23 refers to a diagnosis of dependence on stimulants other than cocaine or amphetamines, accompanied by withdrawal symptoms. Stimulants can include substances such as methamphetamine, ecstasy (MDMA), and prescription medications like methylphenidate or amphetamine salts. Dependence is characterized by a compulsive pattern of use, tolerance, and withdrawal symptoms when the substance is reduced or stopped. Withdrawal symptoms may include fatigue, depression, increased appetite, and sleep disturbances. The clinical management of stimulant dependence often involves a combination of behavioral therapies and support groups, as there are currently no FDA-approved medications specifically for stimulant withdrawal. Understanding the nuances of this diagnosis is crucial for effective treatment planning and coding accuracy.
Detailed history of substance use, withdrawal symptoms, and treatment plans.
Patients presenting with withdrawal symptoms after cessation of stimulant use.
Documentation must clearly outline the type of stimulant and the severity of dependence.
Comprehensive mental health evaluation, including co-occurring disorders.
Patients with stimulant dependence experiencing anxiety or depression.
Consideration of dual diagnosis and the impact on treatment outcomes.
Used when assessing a patient for stimulant dependence.
Comprehensive assessment notes and history.
Addiction specialists should ensure thorough documentation of substance use history.
Common symptoms include fatigue, depression, increased appetite, sleep disturbances, and intense cravings for the substance.
